Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR2 | O95136 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.33 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.33 |
| ▸ | KDM5A | P29375 | 2/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12289212 | 0.85 | HSD17B10 (0.32) | — | |
| SCHEMBL713480 | 0.78 | SPHK1 (0.41) | — | |
| SCHEMBL6850921 | 0.74 | SPHK1 (0.54) | — | |
| SCHEMBL29457699 | 0.73 | LMNA (0.42) | — | |
| SCHEMBL29457698 | 0.73 | LMNA (0.42) | — | |
| SCHEMBL172303 | 0.69 | SIGMAR1 (0.38) | S1PR2S1PR1S1PR3S1PR5KDM5A | |
| SCHEMBL29980358 | 0.68 | CHRM2 (0.30) | — | |
| SCHEMBL12289110 | 0.68 | KDM4C (0.40) | S1PR2S1PR1S1PR3S1PR5KDM5A | |
| SCHEMBL25144534 | 0.67 | SIGMAR1 (0.37) | S1PR2S1PR1S1PR3S1PR5KDM5A | |
| SCHEMBL23945948 | 0.67 | SIGMAR1 (0.46) | S1PR2S1PR1S1PR3S1PR5KDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9908970-B2 | Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method | NEKTAR THERAPEUTICS (US) | 2018-03-06 | — | — | US | disclosed |
| US-20170121459-A1 | POLYMERIC ALPHA-HYDROXY ALDEHYDE AND KETONE REAGENTS AND CONJUGATION METHOD | NEKTAR THERAPEUTICS | 2017-05-04 | — | — | US | disclosed |
| US-9579392-B2 | Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method | NEKTAR THERAPEUTICS (US) | 2017-02-28 | — | — | US | disclosed |
| US-20160144046-A1 | POLYMERIC ALPHA-HYDROXY ALDEHYDE AND KETONE REAGENTS AND CONJUGATION METHOD | NEKTAR THERAPEUTICS | 2016-05-26 | — | — | US | disclosed |
| US-9228053-B2 | Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method | NEKTAR THERAPEUTICS (US) | 2016-01-05 | — | — | US | disclosed |
| US-20130280783-A1 | POLYMERIC ALPHA-HYDROXY ALDEHYDE AND KETONE REAGENTS AND CONJUGATION METHOD | NEKTAR THERAPEUTICS | 2013-10-24 | — | — | US | disclosed |
| US-8492503-B2 | Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method | NEKTAR THERAPEUTICS (US) | 2013-07-23 | — | — | US | disclosed |
| US-20110230618-A1 | Polymeric Alpha-Hydroxy Aldehyde and Ketone Reagents and Conjugation Method | NEKTAR THERAPEUTICS (US) | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160144046-A1 | POLYMERIC ALPHA-HYDROXY ALDEHYDE AND KETONE REAGENTS AND CONJUGATION METHOD | ASPH, ALDH1A1, ADH1C | S1PR2 1752/4885S1PR1 1194/4885S1PR3 1227/4885 |
| US-20130280783-A1 | POLYMERIC ALPHA-HYDROXY ALDEHYDE AND KETONE REAGENTS AND CONJUGATION METHOD | ASPH, ALDH1A1, ADH1C | S1PR2 1752/4885S1PR1 1194/4885S1PR3 1227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.